克唑替尼用于ROS1阳性患者：生物标志物检测的一小步，晚期非小细胞肺癌患者的一大步。 - Suppr

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

作者信息

Juan Oscar, Popat Sanjay

机构信息

Department of Medical Oncology, Hospital Universitari i Politècnic La FE, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain.

Lung Unit, Royal Marsden Hospital, London SW3 6JJ, UK; National Heart & Lung Institute, Faculty of Medicine, Imperial College London, Guy Scadding Building, Cale Street, London SW3 6LY, UK; The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK.

出版信息

Lung Cancer. 2017 Feb;104:131-133. doi: 10.1016/j.lungcan.2016.11.007. Epub 2016 Nov 11.

DOI:10.1016/j.lungcan.2016.11.007

PMID:27863911

Abstract

摘要

相似文献

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

Lung Cancer. 2017 Feb;104:131-133. doi: 10.1016/j.lungcan.2016.11.007. Epub 2016 Nov 11.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med. 2015 Feb 12;372(7):683-4. doi: 10.1056/NEJMc1415359.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med. 2015 Feb 12;372(7):683. doi: 10.1056/NEJMc1415359.

[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].

Bull Cancer. 2017 Apr;104(4):303-310. doi: 10.1016/j.bulcan.2017.01.008. Epub 2017 Feb 22.

ROS1 [corrected].

J Clin Pathol. 2017 Dec;70(12):1001-1009. doi: 10.1136/jclinpath-2016-204244. Epub 2017 Sep 13.

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11.

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Lung Cancer. 2015 Feb;87(2):207-9. doi: 10.1016/j.lungcan.2014.12.011. Epub 2014 Dec 19.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.

ROS1--targeting the one percent in lung cancer.

N Engl J Med. 2014 Nov 20;371(21):2030-1. doi: 10.1056/NEJMe1411319.

引用本文的文献

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Curr Oncol. 2022 Mar 14;29(3):1967-1982. doi: 10.3390/curroncol29030160.

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.

Cancer Med. 2020 May;9(10):3328-3336. doi: 10.1002/cam4.2984. Epub 2020 Mar 13.

Crizotinib inhibition of positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.

Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis.

Oncol Lett. 2018 Oct;16(4):4201-4210. doi: 10.3892/ol.2018.9221. Epub 2018 Jul 26.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in -Positive Non-Small-Cell Lung Cancer.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

Prognostic significance of subclassification of stage IIB lung cancer: a retrospective study of 226 patients.

Oncotarget. 2017 Jul 11;8(28):45777-45783. doi: 10.18632/oncotarget.17405.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

作者信息

Juan Oscar, Popat Sanjay

机构信息

Department of Medical Oncology, Hospital Universitari i Politècnic La FE, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain.

出版信息

Lung Cancer. 2017 Feb;104:131-133. doi: 10.1016/j.lungcan.2016.11.007. Epub 2016 Nov 11.

DOI:10.1016/j.lungcan.2016.11.007

PMID:27863911

Abstract

摘要

相似文献

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

Lung Cancer. 2017 Feb;104:131-133. doi: 10.1016/j.lungcan.2016.11.007. Epub 2016 Nov 11.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med. 2015 Feb 12;372(7):683-4. doi: 10.1056/NEJMc1415359.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med. 2015 Feb 12;372(7):683. doi: 10.1056/NEJMc1415359.

[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].

Bull Cancer. 2017 Apr;104(4):303-310. doi: 10.1016/j.bulcan.2017.01.008. Epub 2017 Feb 22.

ROS1 [corrected].

J Clin Pathol. 2017 Dec;70(12):1001-1009. doi: 10.1136/jclinpath-2016-204244. Epub 2017 Sep 13.

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11.

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Lung Cancer. 2015 Feb;87(2):207-9. doi: 10.1016/j.lungcan.2014.12.011. Epub 2014 Dec 19.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

J Thorac Oncol. 2016 Aug;11(8):1273-1281. doi: 10.1016/j.jtho.2016.04.001. Epub 2016 Apr 9.

ROS1--targeting the one percent in lung cancer.

N Engl J Med. 2014 Nov 20;371(21):2030-1. doi: 10.1056/NEJMe1411319.

引用本文的文献

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Curr Oncol. 2022 Mar 14;29(3):1967-1982. doi: 10.3390/curroncol29030160.

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.

Cancer Med. 2020 May;9(10):3328-3336. doi: 10.1002/cam4.2984. Epub 2020 Mar 13.

Crizotinib inhibition of positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.

Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis.

Oncol Lett. 2018 Oct;16(4):4201-4210. doi: 10.3892/ol.2018.9221. Epub 2018 Jul 26.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in -Positive Non-Small-Cell Lung Cancer.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

Prognostic significance of subclassification of stage IIB lung cancer: a retrospective study of 226 patients.

Oncotarget. 2017 Jul 11;8(28):45777-45783. doi: 10.18632/oncotarget.17405.

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献